品牌 |
Leading Biology | 貨號 |
APR02637G |
產(chǎn)品分類 |
Polyclonal Antibodies | 研究領(lǐng)域 |
|
產(chǎn)品概述 |
We constantly strive to ensure we provide our customers with the best antibodies. As a result of this work we offer this antibody in purified format.
We are in the process of updating our datasheets. If you have any questions regarding this update, please feel free to contact our technical support team.
This product is a high quality TNFAIP3 / A20 Antibody (C-Terminus).
|
||
分子量 |
90kDa
|
||
細(xì)胞定位 |
Antigen Cellular Localization:
Cytoplasm. Nucleus. Lysosome.
|
||
宿主 |
Rabbit
|
||
種屬反應(yīng)性 |
Human, Mouse, Rat
|
||
靶點 |
Human TNFAIP3
|
||
通用名 |
OTUD7C
|
||
基因ID |
|||
UniProt ID |
|||
功能 |
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS- induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.
|
||
總結(jié) |
Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on 'Lys-63'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates 'Lys-63'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate 'Lys-11'-, 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS- induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.
|
||
儲存條件 |
Store at +4°C short term. For long-term storage, aliquot and store at -20°C or below. Stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles.
|
||
應(yīng)用 |
WB, IHC-P, IF, E
|
||
稀釋方法 |
IHC-P (5 μg/ml), WB (1-2 μg/ml),
|
||
圖像 |
Immunofluorescence of TNFAIP3 in Human Lung cells with TNFAIP3 antibody at 20 ug/ml. |
||
說明書 |
|||
數(shù)量 |
|
選擇 | 品牌 | 貨號 | 產(chǎn)品名稱 | 規(guī)格 | 分類 | 研究領(lǐng)域 | 說明書 | 數(shù)量 | 目錄價 | |
1 | Leading Biology | APR05963G | EGFR Antibody (Y1092) | 100 μl | Polyclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
2 | Leading Biology | APR03116G | BRCA1 Antibody (aa1847-1863) | 100 μl | Polyclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
3 | Leading Biology | AMM05633G | Bombesin Receptor 2 (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購 詢價 | ||
4 | Leading Biology | APR10986G | AP3B1 Antibody (aa2-14) | 50 μg | Polyclonal Antibodies |
|
¥4950.00 | 訂購 詢價 | ||
5 | Leading Biology | APR11512G | Bestrophin-1 (extracellular) Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購 詢價 | ||
6 | Leading Biology | APG01407G | A3 Adenosine Receptor Antibody | 50 μl | Polyclonal Antibodies |
|
¥6950.00 | 訂購 詢價 |
微信掃描二維碼,隨時隨地與小諾親密接觸,精彩活動,勁爆優(yōu)惠,觸手可得!